Ivonescimab Meets Phase III Overall Survival Endpoint in Biliary Tract Cancer

Company: Akeso · Drug: Ivonescimab · Trial: HARMONi-GI1 (Phase III) · Indication: First-Line Biliary Tract Cancer · Date: August 26, 2026 Summary Akeso reported that the 682-patient, randomized Phase III HARMONi-GI1 trial met its primary overall-survival endpoint at a prespecified interim analysis: ivonescimab plus gemcitabine…